Keytruda® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) – Expanded indication, accelerated approval converted to full approval
December 15, 2023 - Astellas/Pfizer and Merck announced the full FDA approval of Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC).
Top